Opus Genetics Past Earnings Performance
Past criteria checks 0/6
Opus Genetics has been growing earnings at an average annual rate of 21.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 60.2% per year.
Key information
21.5%
Earnings growth rate
43.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 60.2% |
| Return on equity | -79.3% |
| Net Margin | -324.4% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Opus Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 8 | -27 | 14 | 0 |
| 30 Jun 24 | 16 | -14 | 13 | 1 |
| 31 Mar 24 | 19 | -11 | 14 | 0 |
| 31 Dec 23 | 19 | -10 | 12 | 0 |
| 30 Sep 23 | 57 | 29 | 11 | 1 |
| 30 Jun 23 | 45 | 19 | 10 | 10 |
| 31 Mar 23 | 42 | 19 | 8 | 0 |
| 31 Dec 22 | 40 | 18 | 7 | 0 |
| 30 Sep 22 | 0 | -22 | 7 | 0 |
| 30 Jun 22 | 0 | -22 | 7 | 0 |
| 31 Mar 22 | 1 | -24 | 8 | 0 |
| 31 Dec 21 | 1 | -57 | 8 | 0 |
| 30 Sep 21 | 1 | -69 | 8 | 0 |
| 30 Jun 21 | 0 | -66 | 7 | 0 |
| 31 Mar 21 | 0 | -61 | 4 | 0 |
| 31 Dec 20 | 0 | -25 | 3 | 0 |
| 30 Sep 20 | 0 | -8 | 2 | 1 |
| 30 Jun 20 | 0 | -9 | 2 | 2 |
| 31 Mar 20 | 0 | -8 | 2 | 2 |
| 31 Dec 19 | 0 | -6 | 2 | 2 |
Quality Earnings: R3X1 is currently unprofitable.
Growing Profit Margin: R3X1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: R3X1 is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare R3X1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: R3X1 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: R3X1 has a negative Return on Equity (-79.28%), as it is currently unprofitable.